
Network News

Heidelberg, Germany / Paris, France, July 9th, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new initiative with Servier. The two partners will implement BioMed X’s proven XSeed Labs incubator model at Servier’s research and development site in Paris-Saclay. This new XSeed Labs – the first of its kind in Europe […]
read more
Investigating kinase activity in living cells
Scientists build molecular recording tool The ability of protein kinases to transfer a phosphate group to target proteins plays an important role in many cellular processes. Scientists at the Max Planck Institute for Medical Research in Heidelberg have now developed a novel molecular tool that can monitor these kinase activities both spatially and temporally. This […]
read more
The evolution of cancer cells decoded
Cancer does not develop overnight. It can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Center (DKFZ) have now developed a method that allows for the first time to reconstruct the temporal development—the evolution—of cancerous cells from a single […]
read more
Five million euros for research into early cancer detection
Investing in a healthier future: The HORNBACH Group is supporting the new National Cancer Prevention Center in Heidelberg with a donation of five million euros. In the future, a new laboratory will conduct research into more effective early detection and screening methods. “Preventive research is a very important field for the future that deserves a […]
read more
Innovative medical products on their way to the clinic – GeneNovate successfully promotes entrepreneurial thinking in cutting-edge German research
After a pilot last year, GeneNovate, Germany’s first national entrepreneurship program for gene and cell therapies, took place for the second time. All participants in the program met in Berlin on 26 June for the joint closing event. There, they presented a total of 23 research projects to a high-caliber jury of business angels, venture […]
read more
New Publication from Hummingbird Diagnostics GmbH: Early detection of Alzheimer’s disease using small RNAs. Results from the EPAD cohort
Alzheimer’s disease is the most common type of dementia, and early detection is important for better treatment. This study looked at small RNA molecules in the blood to see if they could help identify early signs of Alzheimer’s, especially in people with high levels of amyloid, a key Alzheimer’s marker. Researchers analyzed blood samples from […]
read more
Medicine in the digital age: “MEDI:CUS” cloud for optimal healthcare
Data can save lives. However, in order for health data to be used for the benefit of patients, relevant data must be made available where it is needed. With the MEDI:CUS project, which is funded under the umbrella of the Forum Gesundheitsstandort Baden-Württemberg, the state of Baden-Württemberg is building a secure and data protection-compliant cloud-based […]
read more
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
NORTH CHICAGO, Ill. and SAN DIEGO, June 30, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase 1, in […]
read more
Strategic alliance for rare diseases: RHEACELL and AOP Health enter into strategic partnership to commercialize novel somatic cell therapies in Europe
Heidelberg/Germany, May 27, 2025. RHEACELL announced today that it has entered into an exclusive partnership agreement with the AOP Health Group, who will commercialize RHEACELL’s two stem cell products, EBESANAR® and AMESANAR®, in Europe, Turkey, Israel and the MENA region (Middle East and Northern Africa). RHEACELL retains full commercialization rights to EBESANAR® and AMESANAR® in […]
read more